A closer look at the technologies used by Alnylam
Alnylam
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
100-102 Avenue De Suffren, Paris, Ile-de...Website
www.alnylam.frRevenue
$34 MillionIndustry
About Alnylam
Alnylam Pharmaceuticals is a leader in the development of RNA interference (RNAi) therapies, aiming to transform the lives of individuals affected by rare and genetic diseases. The company has successfully developed five approved RNAi therapies and continues to innovate with a robust pipeline targeting unmet therapeutic needs in various conditions, including hereditary transthyretin amyloidosis and other rare diseases. Alnylam's approach focuses on silencing disease-causing genes to block the production of harmful proteins at their source. With a commitment to expanding the reach of RNAi treatments, Alnylam seeks to benefit millions of patients worldwide.Explore more
SIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Alnylam Tech Stack
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alnylam
Sign Up For FreeTo access detailed company insights
Alnylam Pharmaceuticals is a leader in the development of RNA interference (RNAi) therapies, aiming to transform the lives of individuals affected by rare and genetic diseases. The company has successfully developed five approved RNAi therapies and continues to innovate with a robust pipeline targeting unmet therapeutic needs in various conditions,... Read More
